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Abstract 
Background 
 
Childhood cancer is a rare but leading cause of morbidity and mortality. Established risk factors, 
accounting for <10% of incidence, have been identified primarily from case‐control studies. 
However, recall, selection and other potential biases impact interpretations particularly, for modest 
associations. A consortium of pregnancy and birth cohorts (I4C) was established to utilise 
prospective, pre‐diagnostic exposure assessments and biological samples. 
 
Methods 
Eligibility criteria, follow‐up methods and identification of paediatric cancer cases are described for 
cohorts currently participating or planning future participation. Also described are exposure 
assessments, harmonisation methods, biological samples potentially available for I4C research, 
the role of the I4C data and biospecimen coordinating centres and statistical approaches used in 
the pooled analyses. 
 
Results 
Currently, six cohorts recruited over six decades (1950s‐2000s) contribute data on 388 120 
mother‐child pairs. Nine new cohorts from seven countries are anticipated to contribute data on 
627 500 additional projected mother‐child pairs within 5 years. Harmonised data currently includes 
over 20 “core” variables, with notable variability in mother/child characteristics within and across 
cohorts, reflecting in part, secular changes in pregnancy and birth characteristics over the 
decades. 
 
Conclusions 
The I4C is the first cohort consortium to have published findings on paediatric cancer using 
harmonised variables across six pregnancy/birth cohorts. Projected increases in sample size, 
expanding sources of exposure data (eg, linkages to environmental and administrative databases), 
incorporation of biological measures to clarify exposures and underlying molecular mechanisms 
and forthcoming joint efforts to complement case‐control studies offer the potential for 
breakthroughs in paediatric cancer aetiologic research. 
 
1 INTRODUCTION 
While cancer in children and adolescents is rare worldwide, it remains a leading cause of morbidity 
and mortality despite notable improvements in survival.1 Established risk factors include prenatal 
exposure to diagnostic X‐ rays,2 genetic syndromes3 and high birthweight4that combined, account 
for <10% of childhood cancer (CC) incidence.5 More recently, pooled case‐ control studies of 
childhood leukaemia (CL) suggest modestly increased risks associated with residential painting 
and pesticide use and pre‐ labour caesarean delivery6-8and slightly decreased risks from day care 
attendance, extended breast feeding, and maternal vitamin and folic acid supplement 
use.9, 10 Known and suspected risk factors for CC2 are briefly summarised in Appendix S1. 
Timing of exposure appears to be associated with variable CC risks, with prenatal and early 
postnatal periods being particularly vulnerable windows.2, 11 Increasing recognition of aetiologic 
differences by subtype2 underscores the need for case‐ control studies evaluating large numbers 
of distinct CC entities. While well‐ designed case‐ control studies can yield valid estimates, 
inherent limitations such as recall bias (differential recall of past exposures by case versus control 
mothers), selection bias (differential participation according to characteristics such as educational 
level or exposure status of cases compared with controls) and reverse causality may affect risk 
estimates and interpretation. 
To complement and address methodologic limitations of case‐ control studies, pooling of multiple 
pregnancy/birth cohorts such as those involved in the International Childhood Cancer Consortium 
(I4C) could verify case‐ control study findings, identifying new risk factors and mechanisms of 
carcinogenesis.12, 13 Biospecimens collected prospectively are an advantage of prospective 
pregnancy/birth cohort studies for exploring CC aetiology, although a few case‐ control studies 
have accessed archived pre‐ diagnostic newborn blood spots14 or cord blood.15 
Our objective was to report on the progress made by the I4C, furthering the description of Brown 
et al,16 in developing a platform through a collaborative network, that provides access to repeated 
exposure “measurement” data and biospecimens. We also describe challenges and future 
directions including collaborations with a consortium of case‐ control studies. 
2 METHODS 
2.1 Overview, structure and operations 
The overarching goal of the I4C is to understand the aetiology and mechanistic underpinnings of 
CC by exploiting prospectively collected exposure and biomarker data. The I4C Steering 
Committee includes lead investigators from cohorts, clinicians, paediatric cancer epidemiologists, 
molecular epidemiologists, exposure assessment experts and 
funders (https://www.mcri.edu.au/research/projects/international-childhood-cancer-cohort-
consortium-i4c/i4c-consortium). The International Data Coordinating Centre (IDCC) at the 
Murdoch Children's Research Institute (MCRI) in Melbourne Australia houses the cohort data, 
manages data transfers, harmonises variables, develops pooled datasets, provides scientific input, 
and ensures the confidentiality, privacy, and security of the data. Additionally, the International 
Biospecimen Coordinating Center (IBCC) at the International Agency for Research on Cancer 
(IARC) in Lyon, France, facilitates the pooling of biological samples. The I4C projects are 
conducted through working groups and annual open scientific meetings attended by investigators 
from participating and additional emerging cohorts and other experts. 
2.2 Study populations 
2.2.1 Eligibility criteria 
Cohorts eligible for inclusion in the I4C need to recruit mothers during pregnancy or around 
delivery. Eligible cohorts must systematically ascertain cases of CC in the offspring and should 
include questionnaire and/or other exposure data that address key CC aetiology‐ related 
hypotheses. The specific goals and original outcomes of the individual cohorts (eg, pregnancy 
complications and/or serious chronic childhood conditions) may vary, but critical data items include 
parental and offspring demographic, life style, medical, reproductive, environmental factors and 
parental occupational information. Specific responsibilities of newly joining or participating I4C 
cohorts include sharing of data (and biospecimens‐  if available) for current and future proposals. 
2.2.2 Currently contributing cohorts 
Six cohorts currently contribute data on cancer cases, exposure data and biospecimens (if 
available) as described in Table 1; more details are available in the published cohort descriptions. 
2.3 Data sharing 
Data sharing and material transfer agreements for the I4C were developed and approved by MCRI 
Ethics Committee and sent to cohort investigators for approval by their Ethics Committees. Only 
anonymised data were requested (see Appendix S2). 
2.4 Follow‐ up methods 
Strategies and time points for follow‐ up varied (Table 1). Follow‐ up methods included postal 
mailings of self‐ administered questionnaires (ALSPAC, DNBC, MoBa), phone‐ administered 
questionnaires (DNBC, TIHS), letters to primary care physicians requesting medical records 
(CPP), field staff visits to extract medical record data (CPP, ALSPAC, JPS, TIHS), home visits 
(TIHS) and/or linkages with hospital and other national registry data (ALSPAC, DNBC, MoBa, JPS, 
TIHS). Follow‐ up response rates for the six participating cohorts were around 60%‐ 70% for most 
cohorts ≥7 years postnatal. 
2.5 CC case ascertainment and classification 
2.5.1 Ascertainment 
For participating cohorts, identification of CC cases has been reliant on linkage to national 
(ALSPAC, DNBC, MoBa and JPS) or state (TIHS) cancer registries except for CPP. The latter 
relied on medical records17 and indirect methods.18 Each potential cancer diagnosis in the CPP 
was reviewed by two board‐ certified paediatricians. 
2.5.2 Classification 
To date, age at diagnosis for CC has been < 15 years, but going forward, will extend to < 20 years. 
Tumours were classified into six major groups based on the International Classification of Diseases 
for Oncology (ICD‐ 0) Third Edition.19 For cohorts with IRB approval to access more detailed 
information, the following was provided: gender, date of birth, date of diagnosis, ICD‐ 10 code, 
3‐ digit ICD‐ 0‐ 3 topographic code and 4‐ digit ICD‐ 0‐ 3 morphology code. ICD‐ 0‐ 3 
morphology codes for leukaemia included 9800‐ 9948, gliomas 9380‐ 9480 and lymphomas 
9590‐ 9729. From this information, the IDCC used the following six groupings: any cancer, any 
leukaemia, acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), any 
lymphomas, any central nervous system (CNS)/brain tumour, or other cancers. Due to small 
numbers and confidentiality issues, ALSPAC provided only any cancer, any leukaemia and acute 
lymphoblastic leukaemia. For DNBC, MoBa and JPS, mandatory reporting of cancer cases to the 
respective registries has been in place since the 1940s to 1960s with completeness of coverage 
being ≥96%.20 In the United Kingdom, 2001 reports showed 94% coverage of cancers ascertained 
during 1971‐ 1989.21 Since CPP cases were identified through indirect methods, some cancer 
cases may have been missed. 
2.6 Exposure data 
2.6.1 Identification of data domains and specific variables associated with CC 
Thirty domains were established for key exposures (eg, birthweight, folic acid supplements, and 
others; see Tables 4‐ 6). The IDCC will submit requests to obtain additional data if needed for 
future proposals (See Appendix S3 for details of the process). While the main domains centre 
around the mother and child (see Tables 4, 6), some information on fathers is also available (see 
Table 5). 
2.6.2 Harmonisation of exposure data 
Our approach is similar to other consortia.22-24 Challenges include combining data from different 
racial and ethnic groups, collected over different time intervals or using heterogeneous data 
collection tools, and some variables so disparate that harmonisation was not possible. The 
individual cohorts collected data in a standardised, structured approach from self‐ reported, 
telephone interview or in‐ person administered questionnaires. Each cohort provided anonymised, 
individual‐ level. Data harmonisation was carried out centrally by the IDCC project director (GT) 
with assistance from senior epidemiologists (TD, ALP). Each exposure variable was harmonised 
individually and the data evaluated for consistency within and across variables (see Appendix S4). 
2.7 Biological samples 
Four of the participating cohorts (ALSPAC, DNBC, MoBa and TIHS) have biological specimens 
collected from mothers and/or offspring at various time points prior to the development of any 
cancer. Types of samples include the following: whole blood, serum, urine and placentas from 
mothers; cord blood, blood (neonatal blood spots), hair, nails and teeth from the offspring 
(Appendix S5). All additional emerging cohorts are collecting a variety of biological samples. 
2.8 Identification of additional emerging cohorts 
Two groups of emerging cohorts are currently involved in I4C activities but are not as yet 
contributing cancer cases, exposures or biospecimens to the pool. These are detailed in Table 2. 
Group A includes five cohorts well established in recruitment and follow‐ up, collecting relevant 
data/biospecimens, able to ascertain CC cases, and positioned to begin contributing data to the 
I4C pool within the next few years: the Born in Guangzhou Cohort Study (BGCS‐ China), the 
Etude Longitudinale Française depuis l'enfance (ELFE‐  France), the Nascita ed Infanzia: gli Effetti 
dell'Ambiente (NINFEA‐ Italy), the Japan Environment and Children's Study (JECS‐ Japan) and 
the Korean Children's Environmental Health Study (Ko‐ CHENS‐ Korea). Group B consists of four 
cohorts in various stages of development or early recruitment and follow‐ up from Australia, Brazil, 
China and Taiwan. 
2.9 Housing of data at the IDCC: platform, confidentiality, privacy and security measures 
The data transferred to the IDCC are securely housed on a web‐ based application located on the 
MCRI's secure e‐ Research portal (see Appendix S6). Access is restricted to authorised personnel 
following approval by the I4C Steering Committee and a representative from each study 
contributing to the pooled data set. 
For added security, data files are encrypted before being sent to the IDCC. Most studies have 
excluded unique personal identifiers (eg, name, residential address) and some have excluded 
month and day of birth. Individuals are identified by a study‐specific identification number, and 
additional security is provided by assigning a unique I4C identification number used as the primary 
identifying key. The electronic data is stored at the IDCC on a secure, password protected server. 
The network server, web server and SQL server undergo nightly incremental backups plus a 
monthly full backup to tape for off‐site storage. All users of the data must comply with the data 
sharing agreements. 
2.10 Statistical consultation and support on study designs, data harmonisation, and analyses 
The I4C statistical team includes two senior biostatisticians (SL, GP) who provide input and advice 
on research proposals and undertake statistical analyses using the pooled data set. 
While complete harmonisation of all questionnaire data is not feasible given cohort differences, 
decisions on pooling are based on the specific research question and what could be pooled with 
minimal compromise to the original recorded data. 
2.11 Statistical methods and models used in I4C analysis 
Time to event analyses use Cox proportional hazard regression models. Calculation of 
person‐years of follow‐up is based on the start time defined as the birth date (the date is set to 
zero years); the end time for those with cancer defined as the date of cancer diagnosis; the end 
time for those without cancer defined as the date the child is no longer under observation. 
Statistical issues considered include the following: (a) accounting for different cohorts; (b) handling 
missing data for risk factors using multiple chained imputation techniques; (c) dealing with different 
lengths of follow‐up of the contributing cohorts; (d) examining confounding and effect‐modification 
of postulated risk factors; (e) finding the correct scale for continuous covariates and (f) testing the 
proportional hazard assumption for Cox regression models. Further details and strategies are in 
Appendix S7. 
 
3 RESULTS 
 
3.1 Cohorts currently contributing data 
 
Six cohorts (Table 1) currently contribute data on 388 120 mother‐child pairs as well as less 
extensive paternal data for certain domains (Tables 4‐6). Recruitment periods span over six 
decades from the late 1950s (CPP), mid‐1960s to mid‐70s (JPS), late 1980s (TIHS), early 1990s 
(ALSPAC), late 1990s (DNBC) and to early 2000s (MoBa). The cohorts range in size from 10 625 
(TIHS) to 110 000 (MoBa) mother‐child pairs. Time points for contacting mothers varied, with 
whole cohort follow‐up ending for the TIHS cohort at 12 weeks, at 7 years for the CPP and ongoing 
for ALSPAC, DNBC and MoBa (Table 1). 
 
3.2 Additional emerging cohorts 
 
Preliminary information about the targeted sample size, planned recruitment years, timing and 
source of recruitment and data collection points for the new cohorts is in Table 2. In summary, nine 
new cohorts within seven countries are collecting data on 627 500 mother‐child pairs, with six 
recruiting mothers during pregnancy and the remaining cohorts at birth (ELFE from Group A and 
Gen V and TBCS from Group B). 
 
3.3 Childhood cancer ascertainment by major category 
 
The 675 CC cases ascertained in the six participating cohorts to date (see Table 3) include 198 
leukaemias (141 acute lymphoblastic leukaemia), 65 lymphomas, 161 brain tumours and 251 
cancers of other types. Based on the I4C target of 1 million mothers and children pooled from the 
participating and emerging cohorts, it is estimated that the I4C has the potential to accrue 2952 
cases of CC (diagnosed <20 years) of which 791 will be CL.25 
 
3.4 Information at the IDCC according to data domain and specific exposures 
 
Available data in the key exposure domains for mothers, fathers and offspring are shown in 
Tables 4-6. Appendix S1 also lists information on known and suspected risk factors for CC, the 
likely/possible time window of effect and whether data are currently available at the IDCC or have 
been collected by the cohorts but have not to date been made available to the IDCC. 
 
3.5 Data harmonisation and descriptive results 
 
To date, harmonised data includes over 20 “core” variables. Tables 7-9 reveal variability in 
characteristics of subjects based on data collected within and across cohorts that may reflect 
secular changes in pregnancy and birth characteristics and societal changes over the six decades 
of recruitment. Substantial differences are apparent for mean age of mothers at birth of the index 
child (24.3, youngest age [CPP] to 30.5, oldest age [DNBC]); mean height (160.9 [CPP] to 
168.1 cm [MoBa]); prevalence of smoking during pregnancy (11% [MoBa] to 51% [TIHS]). For 
offspring, the gender of the offspring enrolled in the cohort ranged from 50% (MoBa) to 69% male 
(TIHS‐  due to selection criteria favouring males given their higher risk of SIDS, the disease of 
focus when the cohort was established); caesarean section delivery (5% [CPP and JPS] to 21% 
[TIHS]); mean birthweight in grams (3108 [TIHS] to 3560 [DNBC]); history of any breast feeding to 
6 months (63% [DNBC, TIHS] to 77% [MoBa]); and paid childcare during the first 6 months (0.1% 
[ALSPAC] to 6% [DNBC]). 
As harmonisation proceeded, emerging cohorts requested information about data collection 
strategies and forms to facilitate future pooling of data. In response, the IDCC has developed a 
“New Cohort Protocol Support Package (NCPS)” to provide researchers with a standardised format 
for the collection of exposure data for aetiologic studies (see Appendix S8). 
 
3.6 Publications 
 
The first I4C publication using a pooled data set examined the association between birthweight and 
risk of CC and maternal adiposity measures as potential effect modifiers. A linear relationship was 
demonstrated for increasing risk of any CC and childhood leukaemia with each kilogram increase 
in birthweight adjusted for gender and gestational age. No significant interactions were seen with 
maternal pre‐pregnancy overweight or pregnancy weight gain. Birthweight >4000 g was linked with 
non‐leukaemia cancers but, only among children diagnosed at age three or older.4 
I4C members have described a new optimised method for extracting DNA from neonatal dried 
blood spots for application in methylome profiling26, 27 using samples from several of the 
contributing cohorts. A review paper describes the characteristics of the epigenome as a key 
component of foetal exposure in evaluating in utero exposures and childhood cancer risk.28 More 
recently, I4C members have begun cataloguing—omics signatures of early‐life factors that could 
be associated with CC.29, 30 These signatures will be analysed across the different I4C cohorts 
with available biological samples. This work will complement the I4C questionnaire‐based 
epidemiological investigations and may provide mechanistic insights into CC aetiology. 
 
3.7 Ongoing data analyses 
 
Current efforts are focused on: examining prospectively, the association of birth order and CL and 
the potential modifying roles of paternal age and birthweight; parental occupational exposure to 
pesticides, animals, and organic dust and risk of CC utilising geocoded residential addresses 
(using DNBC in the first analysis) to evaluate pesticide use near the residences during the 
pregnancy as well as parental occupational exposure; prenatal maternal folic acid supplementation 
and risk of CC; maternal infections during pregnancy and CC; epigenetic precursors of CL. 
3.8 Process for requesting data for new research proposals 
The I4C Steering Committee facilitates data sharing provided that all approvals are in place. The 
process for requesting data from any of the I4C contributing cohorts and the parallel steps 
undertaken at the IDCC to provide the data are in Appendix S2. 
 
4 COMMENT 
 
The I4C is a valuable resource comprising both questionnaire‐based epidemiological data and 
biological samples offering unique opportunities to advance our understanding of the aetiology and 
mechanisms of carcinogenesis in children. It is the first established pregnancy/birth cohort 
consortium to have published findings on CC using harmonised variables across six cohorts. 
The six participating cohorts provide an extensive set of covariates that can be leveraged with 
different follow‐up periods ranging from pregnancy to adolescence. Ongoing collaborative work 
involves molecular cancer epidemiology studies and the potential for evaluation of other 
biomarkers. 
One of the aims of the I4C has been to verify the associations reported by case‐control studies for 
the more commonly examined exposures such as birthweight. Our analysis of birthweight included 
377 cases of any cancer (115 CL and 98 ALL) and showed a linear relationship for each kilogram 
increment for any leukaemia (Hazard ratio [HR] = 1.35; 95% CI 0.90, 2.02) with similar trends 
observed for ALL.4 Risk estimates from our study of birthweight were similar to those reported in 
the pooled analyses from the Childhood Leukemia International Consortium (CLIC) (7348 cases of 
CL and 12 489 controls) with an odds ratio (OR) of 1.24 for large‐for‐gestational‐age children and 
from a second pooled analysis from the USA, UK and Germany (4075 cases and 12 065 controls) 
with an OR of 1.2 per 1000 g increase in birthweight,31, 32 although a UK and US registry‐based 
case‐control study (40 000 cases and 87 000 controls) reported lower increases of CL per 500 g 
increases of OR = 1.10 for US and 1.07 for UK data.33 
There is a critical role for prospective assessment of exposure using pre‐diagnostic questionnaire 
data and biological samples, but the rarity of CC and identification of an expanding number of 
molecularly different CC subtypes underscores the strengths and limitations of the I4C. Pooling of 
multiple pregnancy and birth cohorts offers prospectively collected risk factor and mechanistic data 
to that obtained from case‐control studies. For example, information about maternal diet, viral 
infections and use of folic acid and other vitamin supplements periconceptionally or during 
pregnancy may not be accurately recalled or available in medical records and thus not captured 
well in case‐control studies. Relatively minor infections during infancy, details of breast feeding and 
day care may similarly not be accurately recalled years later. Despite these potential strengths, 
cohort studies may also suffer from methodologic shortcomings including selection bias (cohort 
members are generally volunteers), under‐ascertainment or misclassification of cancer outcomes, 
loss to follow‐up over time, limited time points of data collection and measurement error 
(depending on the exposure assessment methods and follow‐up time periods). By jointly 
undertaking projects with investigators leading case‐control studies, the strengths of each study 
design can be maximised and the limitations and potential biases can be identified and quantified. 
 
4.1 Future directions 
 
The I4C includes a growing number of participating cohorts and is poised to significantly increase 
its sample size within the next 5 years. I4C studies are incorporating a growing range of exposure 
assessment methods and tools, including Geographic Information Systems (GIS) to assess 
agricultural and pesticide exposures near residences, satellite measurements to measure ambient 
ultraviolet radiation and assignment of occupational exposures using job exposure matrices. 
Statistical approaches include sophisticated methods for quantifying temporal and age effects in 
the assessment of associations between exposure and outcome. Collaborative efforts have 
recently been undertaken to develop joint projects with the Childhood Leukemia International 
Consortium during future planned joint meetings. The prospects for combining multiple sources of 
pre‐diagnostic exposure data and biological samples in conjunction with collaboration with other 
birth cohort and paediatric cancer case‐control consortia offer the potential for future 
breakthroughs in paediatric cancer aetiologic research. 
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